Hepatitis B core-related antigen (HBcrAg): an alternative to HBV DNA to assess treatment eligibility in Africa

BackgroundTo eliminate hepatitis B virus (HBV) infection, it is essential to scale up testing and treatment. However, conventional tools to assess treatment eligibility, particularly nucleic acid testing (NAT) to quantify HBV DNA, are hardly available and affordable in resource-limited countries. We...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2019-05
Main Authors: Shimakawa, Yusuke, Ndow, Gibril, Njie, Ramou, Freeya Njai, Harr, Takahashi, Kazuaki, Akbar, Mohammad Fazle, Cohen, Damien, Nayagam, Shevanthi, Jeng, Adam, Ceesay, Amie, Sanneh, Bakary, Baldeh, Ignatius, Imaizumi, Masayasu, Moriyama, Kazushige, Aoyagi, Katsumi, d'Alessandro, Umberto, Mishiro, Shunji, Chemin, Isabelle, Mendy, Maimuna, Thursz, Mark R., Lemoine, Maud
Format: Article
Language:English
Subjects:
Human health and pathology
Infectious diseases
Life Sciences
Microbiology and Parasitology
Virology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundTo eliminate hepatitis B virus (HBV) infection, it is essential to scale up testing and treatment. However, conventional tools to assess treatment eligibility, particularly nucleic acid testing (NAT) to quantify HBV DNA, are hardly available and affordable in resource-limited countries. We therefore assessed the performance of novel immunoassay, hepatitis B core-related antigen(HBcrAg), as an inexpensive (US$
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciz412